|
Showing 1 - 3 of
3 matches in All Departments
With the current advances in chemotherapy and hormonal drugs for
breast cancer, as well as in surgical techniques and procedures, a
revised edition of this popular textbook has become increasingly
necessary. Completely overhauling the existing material, the
editors of this important work have provided a full update of the
area, with colour images, which focuses in particular upon the
topics where there has been most progress and controversy.
This is the third volume of our series Progress in Anti-Cancer
Chemo therapy. Following the strategy of the first two volumes, it
covers selected aspects of progress in this fast moving field of
Oncology, with contribu tions from some of the world's best known
leaders in both basic and clin ical research. This year we focused
on seven areas: Three prominent Clinical investigators reviewed
conceptual advances in cancer research. Dr Buzdar presented a
history and overview of the protection of human subjects who
participate in clinical research, and the mechanisms developed to
assure the ethical conduct of research on human beings. Frei
reviewed an exciting and rapidly moving area of che motherapy of
solid tumors, including a cogent discussion of the issues related
to dose-intensification. Fisher summarized conceptual advances in
our therapeutic approach to breast cancer and the paradigm shifts
that lead us to our current management strategies. From this
summary he pro jected breast cancer research into the future, a
daunting task under any circumstance. Fundamental research in
cancer biology has been responsible for our improved understanding
of the development and progession of malignant disease. Such
understanding will lead to improved diagnosis, therapy, and
eventually, prevention. Isaacs reviews the area of hereditary
breast cancer, a topic undergoing rapid transformation and with
mUltiple impli cations in the daily practice of medicine. Fidler,
an international expert in metastasis research reviews the
potential utility of angiogenesis inhib itors in research and the
therapeutic ramifications."
This is the fourth volume of our series Progress in Anti-cancer
Therapy. For the past four years we have taken the challenge to
select each year, some of the most interesting topics on the wide
field of oncology. As usual, this volume continues the tradition
and covers five cancers (breast, prostate, bladder, lym phoma and
ovarian), the role of HIV and HTLV in cancer, as well as some deve
lopmental pharmacology and behavioral issues. This year, we have
particularly focused our attention on one of the most com mon
(although rarely addressed) cancer accounting for more than 315,00
newly diagnosed cases and 41,000 cancer-related deaths annually
(Landis SH et al., 1999): prostate cancer. Five chapters address
some of the issues concerning this disease. The chap ter by
Schroder describes the hopes and pitfalls of early detection of
prostate cancer. It reviews the literature on screening studies
that have been performed both in the US and in Europe. These
studies suggest that cancer mortality could be reduced by screening
for prostate cancer, mostly through PSA testing. However, the
effectiveness of early detection still needs to be definitely
confir med and ongoing randomized studies are described, the
results of which will probably help the medical community determine
the worth of PSA-based scree ning for prostate cancer. On the same
hand, the paper from von Eschenbach is reviewing the clinical
problems that are related this disease."
|
|